Interius BioTherapeutics has filed a notice of an exempt offering of securities to raise $21,451,331.00 in New Debt Financing.
According to filings with the U.S. Securities and Exchange Commission, Interius BioTherapeutics is raising $21,451,331.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Philip Johnson played a key role…
